PX-3

PX-3
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C24H28N4O2
Molar mass 404.5 g/mol
3D model (JSmol)

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2][3]

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.[4][5]

Legality

Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.[6]

See also

References

  1. ↑ "APP-CHMINACA". Cayman Chemical. Retrieved 24 June 2015.
  2. ↑ "Patent WO/2009/106980 - Indazole derivatives".
  3. ↑ "EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert". Retrieved 24 June 2015.
  4. ↑ "EWS Forum - In Schweden wurde die neue psychoaktive Substanz N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-APP-PICA) identifiziert". Retrieved 24 June 2015.
  5. ↑ "EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert". Retrieved 24 June 2015.
  6. ↑ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.